The chief executive officer of Chimera Bioengineering discussed CBIO-007 and its planned IND submission for colorectal and triple negative breast cancer.
Vlad Hogenhuis, MD, MBA
Advertisement
Articles by Vlad Hogenhuis, MD, MBA
Advertisement
Latest Updated Articles
Vlad Hogenhuis, MD, MBA, on Developing Controllable CAR Ts for Solid TumorsPublished: October 29th 2022 | Updated:
Advertisement
Advertisement
